CEO Ichor Therapeutics
Kelsey is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, He has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated contract research organization that focuses on pre-clinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), and protein engineering (RecombiPure, Inc.). Kelsey has received graduate-level training in medicine, business, and laboratory research.